MannKind Corporation (NASDAQ:MNKD) announced after the bell on Tuesday that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that AFREZZA Inhalation Powder be granted marketing approval. MannKind Corporation (NASDAQ:MNKD) shares after opening at $7.75 on last trade day and at the end of the day closed at $6.99. Company price to cash ratio in past twelve months was calculated as 37.24. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 20.52%.
Radnet Inc (NASDAQ:RDNT) issued its quarterly earnings data on Monday. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.02, Stock Ratings Network reports. The company had revenue of $178.30 million for the quarter, compared to the consensus estimate of $172.97 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. RadNet Inc.(NASDAQ:RDNT) shares advanced 11.81% in last trading session and ended the day on $3.22. RDNT return on assets ratio is recorded as 0.30%. RadNet Inc.(NASDAQ:RDNT) yearly performance is 13.38%.
Zalicus Inc (NASDAQ:ZLCS) announced that a poster developed in collaboration with colleagues from Eisai Inc. and a podium presentation with collaborators from Sanofi will be given at the American Association for Cancer Research (AACR) 2014 Annual Meeting which takes place April 5-9, 2014 in San Diego, CA. These preclinical data, which were generated in separate studies by leveraging the Zalicus combination High-throughput screening (cHTS™) technology platform, demonstrate the potential to identify (or highlight) synergistic activity of the Eisai nontaxane eribulin and the Sanofi antibody drug conjugate SAR3419, through drug combinations. Zalicus Inc (NASDAQ:ZLCS) shares moved up 8.94% in last trading session and was closed at $1.34, while trading in range of $1.22 – $1.34. Zalicus Inc (NASDAQ:ZLCS) year to date (YTD) performance is 20.72%.
Bio-Path Holdings Inc (NASDAQ:BPTH) announced operational and financial results for the year 2013. Net loss for the year 2013 was $(3,266,013), compared to a Net Loss of $(2,582,537) for the year 2012. The increase in net loss was due to an increase of $648,553 in general and administrative expense, which was due to an increase in stock option expense for management, officers and directors totaling $661,861, a non-cash expense that is based upon the Black Scholes fair value of the options grants. Bio-Path Holdings Inc (NASDAQ:BPTH) weekly performance is -6.46%. On last trading day company shares ended up $2.46. Bio-Path Holdings Inc (NASDAQ:BPTH) distance from 50-day simple moving average (SMA50) is -35.77%. Analysts mean target price for the company is $3.00.